Stock AQST AQUESTIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Real-time Estimate Cboe BZX
Other stock markets
 03:07:53 2024-06-03 pm EDT 		5-day change 1st Jan Change
2.925 USD +1.56% Intraday chart for Aquestive Therapeutics, Inc. -5.48% +45.05%
May. 10 Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target MT
May. 08 Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
GL
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
GL
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
AQ
Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target
MT
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
GL
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
AQ
Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (AQST) AQUESTIVE THERAPEUTICS Posts Q1 Revenue $12.1M, vs. Street Est of $12.3M
MT
Aquestive Therapeutics: Q1 Earnings Snapshot
AQ
Aquestive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Aquestive Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024
CI
Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children
MT
Transcript : Aquestive Therapeutics, Inc. - Special Call
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
GL
Aquestive Therapeutics, Inc Receives U.S. FDA Approval and Market Access for Libervant? Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm? (epinephrine) Sublingual Film
CI
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
GL
Aquestive Therapeutics to Present Crossover Study Data for Libervant Buccal Film at 76th Annual Meeting of the American Academy of Neurology
AQ
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
GL
Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AQST Stock
  4. News Aquestive Therapeutics, Inc.